HIV-Associated Cancers

  • Robert Yarchoan
  • Thomas S. Uldrick
  • Mark N. Polizzotto
Chapter

Abstract

HIV-associated cancers are cancers whose incidence is increased in patients with HIV infection, and especially those in which the increased incidence is a result of the HIV infection. These include both AIDS-defining cancers (cancers that confer a diagnosis of AIDS when they occur in HIV-infected persons) and non-AIDS-defining cancers (other cancers whose incidence is increased in HIV infection). The AIDS-defining cancers are Kaposi sarcoma, certain high grade B cell lymphomas, and cervical cancer.

References

  1. Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood. 2004;104(3):810–4.PubMedCrossRefGoogle Scholar
  2. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335(8682):123–8.PubMedCrossRefGoogle Scholar
  3. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004;101(2):317–24.PubMedCrossRefGoogle Scholar
  4. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009;48(5):633–9.PubMedCrossRefGoogle Scholar
  5. Butler LM, Osmond DH, Jones AG, Martin JN. Use of saliva as a lubricant in anal sexual practices among homosexual men. J Acquir Immune Defic Syndr. 2009;50(2):162–7 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].Google Scholar
  6. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep. 1992;41:RR-17.Google Scholar
  7. Centers for Disease Control. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. Morb Mortal Wkly Rep. 1981;30(25):305–8.Google Scholar
  8. Centers for Disease Control. Revision of the case definition of acquired immunodeficiency syndrome for national reporting - United States. Morb Mortal Wkly Rep. 1985;34(25):373–5.Google Scholar
  9. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186–91.PubMedCrossRefGoogle Scholar
  10. Chang Y, Cesarman E, Pessin M, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266: 1865–9.PubMedCrossRefGoogle Scholar
  11. Chokunonga E, Levy LM, Bassett MT, Borok MZ, Mauchaza BG, Chirenje MZ, et al. AIDS and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS. 1999;13(18):2583–8.PubMedCrossRefGoogle Scholar
  12. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–32.PubMedCrossRefGoogle Scholar
  13. Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017–24.PubMedCentralPubMedCrossRefGoogle Scholar
  14. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006a;20(12):1645–54.PubMedCrossRefGoogle Scholar
  15. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006b;24(9):1383–8.PubMedCrossRefGoogle Scholar
  16. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100.PubMedCentralPubMedCrossRefGoogle Scholar
  17. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol. 1995;13(4):996–1003.PubMedGoogle Scholar
  18. Gill P, Tsai Y, Rao AP, Jones P. Clonality in Kaposi’s sarcoma. N Engl J Med. 1997;337(8):570–1 [Discussion 1–2].PubMedCrossRefGoogle Scholar
  19. Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351(9119):1833–9.PubMedCrossRefGoogle Scholar
  20. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33.PubMedCrossRefGoogle Scholar
  21. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003;21(18): 3447–53.PubMedCrossRefGoogle Scholar
  22. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000; 92(22):1823–30.CrossRefGoogle Scholar
  23. Jones JL, Hanson DL, Ward JW. Effect of antiretroviral therapy on recent trends in cancers among HIV-infected. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(4):A38 [Abstract S3].Google Scholar
  24. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336(23):1641–8.PubMedCrossRefGoogle Scholar
  25. Krown SE, Real FX, Cunningham-Rundles S, Myskowski PL, Koziner B, Fein S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. N Engl J Med. 1983;308:1071–6.PubMedCrossRefGoogle Scholar
  26. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309:453–8.PubMedCrossRefGoogle Scholar
  27. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653–9.PubMedCrossRefGoogle Scholar
  28. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116(5): 1167–73.PubMedCentralPubMedCrossRefGoogle Scholar
  29. Martin JN. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and Kaposi sarcoma. Adv Dent Res. 2011;23(1):76–8 [Review].PubMedCrossRefGoogle Scholar
  30. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med. 1999;340(14):1063–70.PubMedCrossRefGoogle Scholar
  31. Martinez-Maza O, Breen EC. B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol. 2002;14(5):528–32.PubMedCrossRefGoogle Scholar
  32. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am. 2003;17(3):673–96, v.Google Scholar
  33. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science. 1990;249: 1533–44.PubMedCrossRefGoogle Scholar
  34. Mitsuyasu RT. Update on the pathogenesis and treatment of Kaposi sarcoma. Curr Opin Oncol. 2000;12(2):174–80.PubMedCrossRefGoogle Scholar
  35. Mitsuyasu R, von Roenn J, Krown S, Kaplan L, Testa M, et al., editors. Comparison study of liposomal doxorubicin (Dox) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi’s sarcoma (AIDS-KS): AIDS Clinical Trial Group (ACTG) protocol 286. American Society for Clinical Oncology, Denver, CO, 17–20 May 1997.Google Scholar
  36. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and without HIV infection. N Engl J Med. 1995;332(18):1181–5.PubMedCrossRefGoogle Scholar
  37. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst. 1997;89(21):1602–8.PubMedCrossRefGoogle Scholar
  38. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS. 1999;13(18):2563–70.PubMedCrossRefGoogle Scholar
  39. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26(7):1027–32.PubMedCrossRefGoogle Scholar
  40. Pneumocystis pneumonia—Los Angeles. Morb Mortal Wkly Rep. 1981;30(21):250–2 [Case reports].Google Scholar
  41. Rabkin CS, Bedi G, Musaba E, Sunkutu R, Mwansa N, Sidransky D, et al. AIDS-related Kaposi’s sarcoma is a clonal neoplasm. Clin Cancer Res. 1995;1(3):257–60.PubMedGoogle Scholar
  42. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19(8):2171–8.PubMedGoogle Scholar
  43. Schiller JT, Lowy DR. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr. 2001;28:50–4.PubMedGoogle Scholar
  44. Shiels MS, Pfeiffer RM, Hall HI, Li J, Goedert JJ, Morton LM, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980–2007. JAMA. 2011a;305(14):1450–9.PubMedCentralPubMedCrossRefGoogle Scholar
  45. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer Burden in the HIV-Infected Population in the United States. J Natl Cancer Inst. 2011b;103(9):753–62.PubMedCentralPubMedCrossRefGoogle Scholar
  46. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21(14):1957–63.PubMedCrossRefGoogle Scholar
  47. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86(4):1276–80.PubMedGoogle Scholar
  48. Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol. 2004;22(8): 1491–500.PubMedCrossRefGoogle Scholar
  49. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008–16.PubMedCentralPubMedCrossRefGoogle Scholar
  50. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. J Clin Oncol. 1998;16(2):683–91.PubMedGoogle Scholar
  51. Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr Opin Oncol. 2012;24(5):495–505 [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Review].Google Scholar
  52. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989–91: changes in incidence in the era of AIDS. Int J Cancer. 1993;54(1):26–36.PubMedCrossRefGoogle Scholar
  53. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer. 2000;82(9):1585–92.PubMedCentralPubMedCrossRefGoogle Scholar
  54. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol. 1998;16(3):1112–21.PubMedGoogle Scholar
  55. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet. 1995;346:799–802.PubMedCrossRefGoogle Scholar
  56. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986a;1:575–80.PubMedCrossRefGoogle Scholar
  57. Yarchoan R, Redfield RR, Broder S. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, Type III/lymphadenopathy-associated virus. J Clin Invest. 1986b;78:439–47.PubMedCentralPubMedCrossRefGoogle Scholar
  58. Yarchoan R, Pluda JM, Perno CF, Mitsuya H, Broder S. Anti-retroviral therapy of HIV infection: current strategies and challenges for the future. Blood. 1991;78(4):859–84.PubMedGoogle Scholar
  59. Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies - the influence of antiviral therapy on pathogenesis and management. Nat Clin Prac Oncol. 2005;2(8):406–15.CrossRefGoogle Scholar
  60. Yarchoan R, Pluda J, Wyvill K, Aleman K, Rodriguez-Chavez IR, Tosato G, et al. Treatment of AIDS-related Kaposi’s sarcoma with interleukin-12: Rationale and preliminary evidence of clinical activity. Crit Rev Immunol. 2007;27(5):401–14.PubMedCrossRefGoogle Scholar
  61. Ziegler JL, Bluming AZ, Morrow Jr RH, Cohen MH, Fife Jr EH, Finerty JF, et al. Burkitt’s lymphoma and malaria. Trans R Soc Trop Med Hyg. 1972;66(2):285–91.PubMedCrossRefGoogle Scholar
  62. Ziegler JL, Miner RC, Rosenbaum E, Lennette ET, Shillitoe E, Casavant C, et al. Outbreak of Burkitt’s-like lymphoma in homosexual men. Lancet. 1982;2:631–3.PubMedCrossRefGoogle Scholar
  63. Ziegler JL, Beckstead JA, Volberding PA, Abrams DI, Levine AM, Lukes RJ, et al. Non-Hodgkin’s lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. New Engl J Med. 1984;311:565–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Robert Yarchoan
    • 1
  • Thomas S. Uldrick
    • 2
  • Mark N. Polizzotto
    • 2
  1. 1.HIV and AIDS Malignancy Branch and Office of HIV and AIDS MalignancyNational Cancer Institute, National Institutes of HealthBethesdaUSA
  2. 2.HIV and AIDS Malignancy Branch, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations